Efficacy and Acceptability of Lanreotide Autogel^® 120 mg at Different Dose Intervals in Patients with Acromegaly Previously Treated with Octreotide LAR

Abstract

Lan-ATG 120 mg injected at intervals of 56, 42 and 28 days provided equivalent hormonal control and QoL to Oct-LAR 10, 20 and 30 mg injected every 28 days, respectively. The proportion of patients preferring Lan-ATG treatment was greater in the longer injection interval groups.